BD Ramps Up Production, Collaborates on New Diagnostic in Response to COVID-19

BD (Becton, Dickinson and Company) was one of several medtech companies that joined President Donald Trump when he declared a national emergency last week. Several medtech executives detailed their response to the novel coronavirus (COVID-19) pandemic. Tom Polen, BD’s CEO and president, reported during President Trump’s announcement that BD is “one of the leading providers of medical devices as well as collection products for testing of coronavirus and we are ramping up our manufacturing capacity to ensure that the right collection devices and testing equipment are ready to address this issue.” BD reported later that it’s ramping up production of its sample collection tools and increasing access to its automated molecular platform for in vitro diagnostics. A BD spokesperson told MD+DI that “The manufacturing facility that makes our collection devices is running 24/7 with ramped up production and we will be supplying hundreds of thousands of swabs/collection devices to the U.S. market every week.” This week BD announced a collaboration with molecular diagnostics company BioGX Inc. in which the two companies have submitted Emergency Use Authorization requests (EUA) to the U.S. FDA for new COVID-19 diagnostic tests to be run on the BD MAX Molecular Diagnostic Platform, a system already used by hundreds of U.S laboratories. The automated unit can process s...
Source: MDDI - Category: Medical Devices Tags: IVD Source Type: news